secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2026-05-14T20:06:45+00:00
Accession:  0001837607-26-000041
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma reports Q1 cash $6.2M; FDA supports ABP-450 biosimilar plan; debt cut >90%
--------------------------------------------------------------------------------

- FDA BPD Type 2a meeting deemed AEON's analytical similarity strategy reasonable for 351(k) pathway.
- Completed $6M PIPE financing and Daewoong note exchange, reducing outstanding debt by >90%.
- Appointed John Bencich as CFO, bringing 25+ years of corporate and capital markets experience.
- Cash and cash equivalents $6.2M at March 31, plus $0.9M April ATM; funds operations into Q3 2026.
- Plans BPD Type 2b meeting in H2 2026 to discuss remaining biosimilar development program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000041/0001837607-26-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000041/aeon-20260514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-26-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer